Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KYTX

Kyverna Therapeutics Inc.

Sep 06 • 04:00PM ET

7.34

Dollar change -0.24
Percentage change -3.17	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO SCHA IWN IWC SBIO VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.63	Insider Own	59.07%	Shs Outstand	43.12M	Perf Week	-8.48%
Market Cap	316.72M	Forward P/E	-	EPS next Y	-4.00	Insider Trans	0.00%	Shs Float	17.66M	Perf Month	5.16%
Income	-91.63M	PEG	-	EPS next Q	-0.76	Inst Own	37.39%	Short Float	16.61%	Perf Quarter	-45.79%
Sales	0.00M	P/S	-	EPS this Y	96.28%	Inst Trans	-	Short Ratio	4.73	Perf Half Y	-74.50%
Book/sh	7.73	P/B	0.95	EPS next Y	-19.95%	ROA	-	Short Interest	2.93M	Perf Year	-
Cash/sh	8.02	P/C	0.91	EPS next 5Y	-	ROE	-	52W Range	6.30 - 35.06	Perf YTD	-75.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-26.98%	52W High	-79.06%	Beta	-
Dividend TTM	-	Quick Ratio	14.86	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	16.51%	ATR (14)	0.70
Dividend Ex-Date	-	Current Ratio	14.86	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	44.01	Volatility	8.04% 8.56%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	41.25
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-119.89%	Payout	-	Rel Volume	0.23	Prev Close	7.58
Sales Surprise	-	EPS Surprise	4.05%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	620.17K	Price	7.34
SMA20	-1.37%	SMA50	-9.83%	SMA200	-54.20%	Trades		Volume	143,706	Change	-3.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
04:05PM	Loading…
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
07:00AM	Loading…
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Karen Marie	Chief Technology Officer	Jun 06 '24	Option Exercise	4.42	9,636	42,591	9,636	Jun 10 06:56 PM
Jones Ryan Alexander	Chief Financial Officer	May 28 '24	Option Exercise	0.73	18,016	13,152	43,950	May 29 04:33 PM
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14 07:04 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14 05:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12 05:51 PM

Open in Screener

ANNX

Annexon Inc

Sep 06 • 04:00PM ET

5.75

Dollar change -0.07
Percentage change -1.20	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO DFAC IWC DFAS VFMO AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.22	Insider Own	20.56%	Shs Outstand	105.65M	Perf Week	-3.04%
Market Cap	607.49M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	0.02%	Shs Float	83.93M	Perf Month	6.68%
Income	-115.16M	PEG	-	EPS next Q	-0.26	Inst Own	86.20%	Short Float	8.67%	Perf Quarter	-2.38%
Sales	0.00M	P/S	-	EPS this Y	44.78%	Inst Trans	8.99%	Short Ratio	4.30	Perf Half Y	17.11%
Book/sh	3.42	P/B	1.68	EPS next Y	-16.58%	ROA	-36.04%	Short Interest	7.27M	Perf Year	131.85%
Cash/sh	3.49	P/C	1.65	EPS next 5Y	38.60%	ROE	-42.20%	52W Range	1.57 - 8.40	Perf YTD	26.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.69%	ROI	-29.61%	52W High	-31.55%	Beta	1.26
Dividend TTM	-	Quick Ratio	21.81	Sales past 5Y	0.00%	Gross Margin	-	52W Low	266.24%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	21.81	EPS Y/Y TTM	38.27%	Oper. Margin	0.00%	RSI (14)	49.21	Volatility	6.72% 5.99%
Employees	71	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.50
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	51.36%	Payout	-	Rel Volume	0.35	Prev Close	5.82
Sales Surprise	-	EPS Surprise	-0.22%	Sales Q/Q	-	Earnings	Aug 12 BMO	Avg Volume	1.69M	Price	5.75
SMA20	-0.93%	SMA50	1.58%	SMA200	15.38%	Trades		Volume	594,875	Change	-1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
04:05PM	Loading…
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:40AM	Loading…
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Loading…
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%
Jan-17-24 11:06AM	Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How (Zacks)
Jan-07-24 08:00PM	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases (GlobeNewswire)
Dec-27-23 06:30AM	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 05:27PM	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +29.51%
05:10PM	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint (GlobeNewswire)
05:08PM	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway (GlobeNewswire)
Dec-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-23 04:01PM	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +8.37%
Nov-14-23 07:20PM	Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) +9.73%
Nov-13-23 06:30AM	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results (GlobeNewswire) +6.35%
Nov-09-23 06:30AM	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 06:30AM	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy (GlobeNewswire) +8.33%
Oct-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Sep-19-23 06:30AM	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-23 09:35AM	Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX) (Zacks)
Aug-07-23 06:30AM	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-23 12:00PM	Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy (GlobeNewswire)
Jul-27-23 06:30AM	Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.82%
Jul-24-23 06:30AM	Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023 (GlobeNewswire)
Jun-14-23 08:36AM	Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation (Simply Wall St.) -5.48%
May-30-23 10:40AM	Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why (Zacks)
May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%
May-16-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.46%
May-08-23 04:01PM	Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Apr-11-23 06:30AM	Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.95%
Mar-25-23 08:04AM	One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year (Simply Wall St.)
Mar-06-23 06:30AM	Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire) -6.77%
Feb-27-23 06:30AM	Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-16-23 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-23 07:35AM	Annexon, Inc.'s (NASDAQ:ANNX) Intrinsic Value Is Potentially 27% Above Its Share Price (Simply Wall St.)
Jan-17-23 04:30PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-23 09:00AM	Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises (GlobeNewswire)
Jan-06-23 06:30AM	Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio (GlobeNewswire) +5.29%
Jan-04-23 06:30AM	Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet (Zacks)
Nov-21-22 06:13AM	We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Nov-17-22 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 09:55AM	How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246% (Zacks)
Nov-03-22 06:30AM	Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 (GlobeNewswire)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 05 '24	Sale	5.64	5,500	31,020	10,000	Sep 06 04:30 PM
Yednock Ted	Officer	Sep 05 '24	Proposed Sale	5.64	5,500	31,020		Sep 05 10:15 AM
Carson William H.	Director	Sep 03 '24	Buy	5.48	3,200	17,536	19,200	Sep 04 04:34 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Aug 29 '24	Sale	5.95	5,500	32,725	15,500	Aug 30 06:00 PM
Yednock Ted	Officer	Aug 29 '24	Proposed Sale	5.95	5,500	32,725		Aug 29 02:08 PM
Carson William H.	Director	Aug 01 '24	Buy	6.24	3,200	19,968	16,000	Aug 05 07:53 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 15 '24	Sale	6.02	784	4,720	94,622	Jul 17 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 15 '24	Sale	6.03	1,104	6,657	86,468	Jul 17 04:48 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 15 '24	Sale	6.02	1,106	6,658	71,365	Jul 17 04:46 PM
Carson William H.	Director	Jul 01 '24	Buy	5.00	3,200	16,000	12,800	Jul 02 05:43 PM
Carson William H.	Director	Jun 03 '24	Buy	4.83	3,200	15,459	9,600	Jun 05 04:23 PM
Carson William H.	Director	May 01 '24	Buy	4.68	3,200	14,982	6,400	May 03 04:15 PM
Carson William H.	Director	Apr 08 '24	Buy	6.07	3,200	19,411	3,200	Apr 10 07:17 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 20 '24	Sale	5.53	2,593	14,339	82,058	Feb 21 04:31 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 20 '24	Sale	5.51	2,604	14,348	72,471	Feb 21 04:31 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 20 '24	Sale	5.48	1,951	10,691	85,641	Feb 21 04:31 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 12 '24	Sale	5.53	1,349	7,460	48,592	Feb 14 07:59 PM
Love Douglas	PRESIDENT AND CEO	Feb 12 '24	Sale	5.54	5,782	32,032	196,121	Feb 14 07:56 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 12 '24	Sale	5.54	1,809	10,022	45,651	Feb 14 07:54 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 12 '24	Sale	5.54	1,810	10,027	36,075	Feb 14 07:52 PM
Yednock Ted	EVP & Chief Innovation Officer	Dec 27 '23	Option Exercise	1.63	21,000	34,176	21,000	Dec 29 04:12 PM
Yednock Ted	EVP & Chief Innovation Officer	Dec 27 '23	Sale	4.52	21,000	94,966	0	Dec 29 04:12 PM
Satter Muneer A	Director	Dec 26 '23	Buy	2.88	350,000	1,008,000	7,406,024	Dec 28 04:30 PM

KYTX

Kyverna Therapeutics Inc.

ANNX

Annexon Inc

Upgrade your FINVIZ experience